Acadia pharmaceuticals announces change in research and development leadership

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that doug williamson, m.d., executive vice president, head of research and development, will be leaving the company to pursue other opportunities. dr. williamson joined acadia in january 2023 and will continue in his role during a transitional period. the company has initiated a search for his replacement. about acadia pharmaceuticals acadia is advancing breakthroughs in neuroscience to elevate life. for 30 y.
ACAD Ratings Summary
ACAD Quant Ranking